TMCI Q1 2026 Earnings Call Summary

Revenue: $47.2 million, a 10% decline year-over-year, primarily due to a shift towards lower-priced minimally invasive products and reduced bunion procedure kit sales.
Gross Margin: 79.3%, slightly down from 79.7% in Q1 2025.
Operating Expenses: $54.6 million, reduced from $57.5 million in the prior year.
Net Loss: $18 million ($0.28 per share), compared to a net loss of $15.9 million ($0.25 per share) in Q1 2025.
Adjusted EBITDA: Loss of $5.5 million, worsening from a loss of $3.8 million in Q1 2025.
Cash Position: Increased to $51.9 million from $48.4 million at year-end 2025.

Transitioning from a focus solely on Lapiplasty to a comprehensive bunion solutions company with multiple new procedure innovations.
Launched three new bunion systems in 2025, which have reportedly doubled the accessible market compared to Lapiplasty alone.
Early adoption of new systems is promising, with 35% of the Lapiplasty surgeon user base incorporating at least one of the new systems.
Continued focus on expanding the product portfolio, including the upcoming launch of the Lapiplasty Lightning platform and the SuperBite compression screw system, aimed at enhancing market penetration and addressing a broader range of surgical needs.

Reaffirmed 2026 revenue guidance of $202 million to $212 million, indicating a decline of 5% to 0% compared to 2025.
Anticipates revenue declines to improve in the latter half of 2026, particularly in Q4, driven by increased case volumes and new product launches.
Expected adjusted EBITDA loss for the full year to be between $4 million and $6 million.
Projected a 50% reduction in cash usage for 2026 compared to 2025.

Revenue decline of 10% in Q1, attributed to macroeconomic pressures and a shift in product mix.
Ongoing headwinds from ASP (average selling price) dynamics due to the introduction of lower-priced products.
Concerns about the overall market environment for elective procedures, which has not shown significant improvement.
Competitive pressures are increasing as TMCI expands into the MIS osteotomy market, necessitating effective differentiation and adoption strategies.

Management indicated that ASP headwinds are expected to diminish by Q3 2026 as they anniversary the launch of new products.
Gross margins are anticipated to remain stable, with efforts to maintain high margins despite fluctuations.
Adoption of new products has been strong, with a positive trend in converting existing customers and attracting new ones, although the long-term impact on Lapiplasty adoption remains to be seen.
Management expressed optimism about the potential for growth in 2027, contingent on the successful execution of current strategies and product launches, though formal guidance for 2027 has not yet been provided.
The competitive landscape is evolving, with TMCI seeing both retention of existing customers and new competitive conversions, indicating a growing market presence.

TMCI — Treace Medical Concepts, Inc.